⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propane SCHEMBL1332979 | 0.83 | — | — | |
| Propane SCHEMBL31520293 | 0.82 | — | — | |
| Propane SCHEMBL31520292 | 0.82 | — | — | |
| SCHEMBL509360 | 0.72 | — | — | |
| SCHEMBL12798365 | 0.72 | — | — | |
| SCHEMBL2755338 | 0.72 | — | — | |
| SCHEMBL12758934 | 0.72 | — | — | |
| SCHEMBL18057016 | 0.72 | — | — | |
| Ethylamine SCHEMBL13800313 | 0.72 | — | — | |
| Alcohol SCHEMBL660675 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107076-A1 | CDK2 INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026101971-A2 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4731623-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260077050-A1 | PROTAC DEGRADERS OF SARS-COV-2 MAIN PROTEASE | TEXAS A & M UNIV SYS (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-20250381198-A1 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-12-18 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| US-11497752-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| EP-4010478-A1 | NON-HUMAN ORGANISM FOR PRODUCING TRIACYLGLYCEROL | Rothamsted Research Ltd (GB) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022114728-A2 | COMPOSITION COMPRISING SHMT INHIBITOR OR MTHFR INHIBITOR FOR TREATING BACTERIAL INFECTION | 성균관대학교산학협력단 | 2022-06-02 | — | — | WO | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220034808-A1 | SENSING DEVICES AND CHEMOSENSORS AND COMPOSITIONS RELATING THERETO | ROBERT BOSCH GMBH (DE) | 2022-02-03 | — | — | US | disclosed |
| CN-110407854-B | Novel tetracyclic compounds | 北京加科思新药研发有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-110407854-A | Novel tetracyclic compounds | BEIJING JACOBIO PHARMACEUTICALS CO LTD | 2019-11-05 | — | — | CN | disclosed |